Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
about
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2Protein degradation pathways in Parkinson's disease: curse or blessingEvolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's diseaseLegal but lethal: functional protein aggregation at the verge of toxicityNigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synucleinDopamine signaling in C. elegans is mediated in part by HLH-17-dependent regulation of extracellular dopamine levels.Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli.α-Synuclein fate is determined by USP9X-regulated monoubiquitination.Mutant alpha-synuclein causes age-dependent neuropathology in monkey brainMorphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome InhibitorsInhibition of Protein Ubiquitination by Paraquat and 1-Methyl-4-Phenylpyridinium Impairs Ubiquitin-Dependent Protein Degradation Pathways.The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells.Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease.Adaptation and sensitization to proteotoxic stress.Adaptive changes in autophagy after UPS impairment in Parkinson's disease.The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's diseaseLysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.Synaptic protein alterations in Parkinson's disease.Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.Animal models of Parkinson's disease: a gateway to therapeutics?Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn).The Proteasome Inhibition Model of Parkinson's Disease.Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury.Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration.How does conserved dopamine neurotrophic factor protect against and rescue neurodegeneration of PC12 cells?Repetitive transcranial magnetic stimulation for treatment of lactacystin-induced Parkinsonian rat model.Overview of mouse models of Parkinson's disease.N-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione.A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs
P2860
Q24301070-0A102204-7F50-4117-9C90-52CE53C37304Q27026029-86C7441E-F6B6-4C1E-9783-8B66EF407484Q27350440-56C719A9-C253-489B-9087-9F630D890843Q28084859-26974B7C-22E4-4934-9413-D56A9E04B28CQ30633819-AEBF7C1B-2BCA-4226-A856-1ABA68704E97Q33784944-E9F77F98-77CA-4BCD-AB29-4BE9DE8C4D31Q34085167-EFAA54A8-4F25-494F-ABCD-DB6A435D78CDQ34655246-56C095D6-A4FC-4E19-AF90-267AEFB65D74Q35558701-4FD9F68F-E96D-47B3-AEDC-37E5714D2F45Q35649563-4BC60A40-761F-4F67-9768-797FE43B7907Q35812372-3DF6CF72-E389-41D2-AB78-2DBC34746F4FQ36828581-BAA060FB-A62E-4FD7-A52E-C5F64F660A92Q37200707-93E29842-54ED-4934-9C7B-B2A42F632A58Q37578801-07E30B59-2CAE-4E4D-9D5A-BD0D1457CF9FQ37651678-C0283385-2269-40BE-847B-DADBC0E15528Q37729051-D7C65397-90EB-4E09-ADC0-4A4374F9F6F8Q37845675-A2EE7EEB-4D38-4625-AF34-1B11E7858DE5Q37880734-99A2F35E-2616-494F-994B-0639D30683BDQ37972089-825A47C1-55B2-411B-91A2-0EBEDB67D1B1Q38074340-3C1A1D6B-E953-4F13-A98C-6320669C2990Q38155480-5E902662-81C2-43F6-B813-DA4DA0E35536Q38647359-3F571682-3304-43ED-9392-6F97C9552EC1Q38996038-101838F5-79BF-4AD1-93F8-F81646E34E7BQ39019452-D6916F73-1013-413B-B93C-9C559614E274Q39342788-67463D06-AE8E-48EC-9258-C19DBC1B9F98Q39407652-4B59E85C-0F4F-4516-A7DF-3BB80C91BA1DQ41429895-C5E0B709-1092-42BA-8AB7-04C1DF71B818Q41612526-936FB807-F533-4786-9C45-D5A78C90516EQ42473489-FE8FFAB5-9C42-4193-8B6E-B94B756B4A02Q47919698-8402AC1A-0C10-4FE0-93B8-25356515956AQ52653236-0CEE8A31-EE1B-4EE8-870E-CBF03F2C9749Q53386963-263E7B07-82BE-4CEE-B95D-B357AAA024A2Q57794605-844C28D5-8C03-4198-953B-746E3E90D695
P2860
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@en
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@nl
type
label
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@en
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@nl
prefLabel
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@en
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@nl
P2093
P1476
Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
@en
P2093
P2860
P304
P356
10.1111/J.1471-4159.2010.06914.X
P407
P577
2010-08-19T00:00:00Z